Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients

C Cohen; JM Molina; P Cahn; B Clotet; J Fourie; B Grinsztejn; W Hao; M Johnson; K Supparatpinyo; HM Crauwels; L Rimsky; S Vanveggel; P Williams; K Boven

Journal ArticleOPEN ACCESS

Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients

Cohen C
Molina J
Cahn P
et al.

Journal of the International AIDS Society (2010) 13(S4)

DOI: 10.1186/1758-2652-13-s4-o48

N/ACitations

6Readers

Abstract

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK

Cite

CITATION STYLE

APA

Cohen, C., Molina, J., Cahn, P., Clotet, B., Fourie, J., Grinsztejn, B., … Boven, K. (2010). Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients. Journal of the International AIDS Society, 13(S4). https://doi.org/10.1186/1758-2652-13-s4-o48

Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients

Abstract

Cite

Register to see more suggestions